| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/08/2006 | WO2003076571A3 Cancer-linked gene as target for chemotherapy |
| 06/08/2006 | US20060123502 Assay methods for identifying RE2-like antagonists, methods of use, and non-human transgenic animals |
| 06/08/2006 | US20060123498 Paks as modifiers of the chk pathway and methods of use |
| 06/08/2006 | US20060123492 Methods of identifying modulators of NMUR2-mediated activity |
| 06/08/2006 | US20060122374 Albumin-fused anti-angiogenesis peptides |
| 06/08/2006 | US20060122142 DNA vaccines for farm animals, in particular bovines and porcines |
| 06/08/2006 | US20060122138 Modulators of EphA2 and EphrinA1 for the treatment of fibrosis-related disease |
| 06/08/2006 | US20060122132 Use of murine genomic regions identified to be involved in tumor developement for the development of anti-cancer drugs and diagnosis of cancer |
| 06/08/2006 | US20060122119 Peptides for use in antitumor immunotherapy |
| 06/08/2006 | US20060122117 Method of treating retinopathies and disorders associated with blood vessel loss |
| 06/08/2006 | US20060122108 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions |
| 06/08/2006 | US20060122107 Method of modulating cellular activity and molecules for use therein |
| 06/08/2006 | US20060122106 Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
| 06/08/2006 | US20060121563 Novel tricistronic vectors and uses therefor |
| 06/08/2006 | US20060121538 Peptides having affinity for the gp120 viral protein and use thereof |
| 06/08/2006 | US20060121529 CpG receptor (CpG-R) and methods relating thereto |
| 06/08/2006 | US20060121522 Stimulating an immune response in human or animal, by administering a gene which LACKS A FUNCTIONAL VHS GENE, lacks a functional gene encoding ICP47, COMPRISES A FUNCTIONAL UL43 GENE, to infect DENDRITIC CELLS; increase gene expression on the surface of tumour cells; protection against cancer; vaccines |
| 06/08/2006 | US20060121521 Cold-adapted equine influenza viruses |
| 06/08/2006 | US20060121480 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 06/08/2006 | US20060121468 Viruses and virus-like particles for multiple antigen and target display |
| 06/08/2006 | US20060121454 diagnosis and treatment of carcinomas, especially breast cancers |
| 06/08/2006 | US20060121447 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis |
| 06/08/2006 | US20060121123 Forming image of sample and coated microparticle mixture by exposing to electromagnetic radiation of infrared or ultraviolet frequency; optical coherence tomography, holography, endoscopy; light, confocal, polarization, interference, and/ormulti-photon microscopy |
| 06/08/2006 | US20060121105 Method of lipid structure preparation |
| 06/08/2006 | US20060121065 Iscom preparation and use thereof |
| 06/08/2006 | US20060121064 Method of preventive treatment of allergy by mucosal administration of an allergy vaccine |
| 06/08/2006 | US20060121063 Group 2 mite polypeptide variants |
| 06/08/2006 | US20060121062 Conjugated hydroxyalkyl starch allergen compounds |
| 06/08/2006 | US20060121061 Attenuated vaccine useful for immunizations against Coccidioides spp. infections |
| 06/08/2006 | US20060121060 administering to animal or bird a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host; protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida |
| 06/08/2006 | US20060121059 Vaccine composition |
| 06/08/2006 | US20060121058 Anti-pneumococcal preparations |
| 06/08/2006 | US20060121057 Combination of local botulinum toxin and oral triptan drug administration; preventing overuse; reducing pain sensory output |
| 06/08/2006 | US20060121056 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics |
| 06/08/2006 | US20060121055 Compositions with enhanced immunogenicity |
| 06/08/2006 | US20060121054 Immunogens; shuttle vectors; do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria; vaccines |
| 06/08/2006 | US20060121053 High cell density process for growth of Listeria |
| 06/08/2006 | US20060121052 And for use in the serological diagnosis of Varicella-Zoster virus infections; lower risk than vaccines from attenuated viable viruses |
| 06/08/2006 | US20060121051 Heat shock fusion-based vaccine system |
| 06/08/2006 | US20060121050 Fusion protein comprising bacillus calmette guerin heat shock protein 65 and the epitope of human prostate specific antigen |
| 06/08/2006 | US20060121049 Chimeric recombinant protein and in vitro diagnosis |
| 06/08/2006 | US20060121048 Encoding at least two full-length mannose-6-phosphate receptors in the antisense configuration, vaccines |
| 06/08/2006 | US20060121047 Use of hmgb polypetides for increasing immune responses |
| 06/08/2006 | US20060121046 Polypeptide comprising the immunogenic portion of wilms' tumor suppressor gene(wt1); tumor-associated antigen for use in cancer immunotherapy |
| 06/08/2006 | US20060121045 Antibody fragments for protection from pathogen infection and methods of use thereof |
| 06/08/2006 | US20060121044 Selecting patients for therapy with a her inhibitor |
| 06/08/2006 | US20060121043 Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections |
| 06/08/2006 | US20060121042 Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| 06/08/2006 | US20060121041 Gpcs as modifiers of the irrtk p21 pathways and methods of use |
| 06/08/2006 | US20060121040 Compositions and methods for treating neuroendocrine tumors |
| 06/08/2006 | US20060121039 Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration |
| 06/08/2006 | US20060121038 treating Alzheimer's disease by administering a humanized or chimeric antibody that specifically binds to an epitope within A beta 3-6 and monitoring the response |
| 06/08/2006 | US20060121037 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/08/2006 | US20060121036 Targeted immunization and plaque destruction against Alzheimer's disease |
| 06/08/2006 | US20060121035 Methods for treating diabetes |
| 06/08/2006 | US20060121034 Treatment for alzheimer's disease and related conditions |
| 06/08/2006 | US20060121033 Using antibodies which bind specifically to DC-SIGN; Agents that bind to ICAM-3 are used to block inhibition of activation of macrophages by DC-SIGN-ICAM-3 interaction and cause inhibition of rheumatoid arthritis symptoms |
| 06/08/2006 | US20060121032 Optimized anti-CD20 monoclonal antibodies having Fc variants |
| 06/08/2006 | US20060121031 Relay vaccine |
| 06/08/2006 | US20060121030 Use of cd 137 antagonists for the treatment of tumors |
| 06/08/2006 | US20060121029 Method and composition for regulating the activity of regulatory t cells |
| 06/08/2006 | US20060121028 Variant IgG3 RITUXAN and therapeutic uses thereof |
| 06/08/2006 | US20060121027 Method for detecting and isolating t lymphocytes that recognize a defined antigen |
| 06/08/2006 | US20060121026 Immunoglobulins devoid of light chains |
| 06/08/2006 | US20060121025 VEGF-related protein |
| 06/08/2006 | US20060121024 Novel class of sterol ligands and their uses in regulation of cholesterol and gene expression |
| 06/08/2006 | US20060121023 Method to decrease nonspecific staining by Cy5 |
| 06/08/2006 | US20060121022 an antibody against protein C or activated protein C (aPC) comprising the heavy chain and light chain complementarity determining regions; used for suppressing activation of the blood coagulation system and antiinflammatory activity; therapy for diseases such as thrombosis and sepsis |
| 06/08/2006 | US20060121021 by which blood cells can be stimulated; amount of required mAbs is lower than when using the same mAbs in a solution, which makes the stimulation independent from the presence or the quality of non-T cells carrying Fc-receptors, and which can be prepared in an easier way under GMP conditions |
| 06/08/2006 | US20060121020 Mixture preparation for enhancing absorption of immunoglobulins in postnatal domestic mammals, and the method thereof |
| 06/08/2006 | US20060121010 Chorionic gonadotropin DNA vaccines and methods |
| 06/08/2006 | US20060121005 Activation and expansion of cells |
| 06/08/2006 | US20060121003 In situ maturation of dendritic cells |
| 06/08/2006 | US20060120999 Protein and peptide expression for passive immunity |
| 06/08/2006 | US20060120997 Cancer therapeutic compositions |
| 06/08/2006 | US20060120996 Vaccine immunotherapy for immune suppressed patients |
| 06/08/2006 | US20060120959 Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| 06/08/2006 | CA2590419A1 Modulation of ovulation |
| 06/08/2006 | CA2589898A1 Modulation of ovulation |
| 06/08/2006 | CA2589885A1 Biomarkers for pre-selection of patients for anti-igf1r therapy |
| 06/08/2006 | CA2589881A1 Mri guided photodynamic therapy for cancer |
| 06/08/2006 | CA2589841A1 Novel pharmaceutical composition useful for vaccines |
| 06/08/2006 | CA2589636A1 Toll like receptor 3 antagonists, methods and uses |
| 06/08/2006 | CA2589379A1 Delaying or preventing onset of multiple sclerosis |
| 06/08/2006 | CA2587507A1 Electroporation of mycobacterium and overexpression of antigens in mycobacteria |
| 06/08/2006 | CA2587493A1 Bacterial packaging strains usefuel for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof |
| 06/08/2006 | CA2587247A1 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof |
| 06/08/2006 | CA2581746A1 Staphylococcus aureus isd protein-based anti-infectives |
| 06/08/2006 | CA2580801A1 Naturally occuring igm antibodies that bind lymphocytes |
| 06/08/2006 | CA2489940A1 Relay vaccine |
| 06/07/2006 | EP1666600A1 Methods for enhancing the efficacy of cancer therapy |
| 06/07/2006 | EP1666499A2 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/07/2006 | EP1666498A2 Soluble CTLA4 molecules, compositions comprising said molecules and uses thereof |
| 06/07/2006 | EP1666489A1 DNA encoding an antigenic protein of eimeria apical membrane antigen 1 and use thereof |
| 06/07/2006 | EP1666487A1 Purification of hbv antigens for use in vaccines |
| 06/07/2006 | EP1666063A2 Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 06/07/2006 | EP1666062A2 Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5c8 |
| 06/07/2006 | EP1666060A1 Adjuvant systems and vaccines |
| 06/07/2006 | EP1666059A1 Novel vaccine containing adjuvant capable of inducing mucosal immunity |
| 06/07/2006 | EP1666058A2 Method of and compositions for immunization with the pseudomonas V antigen |